AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series

AIM ImmunoTech Inc. (NYSE American: AIM), based in Ocala, Florida, has announced that its CEO, Thomas K. Equels, will participate in a “fireside chat” during the Virtual Investor Closing Bell Series on December 4, 2025, at 4:00 PM ET. The discussion aims to shed light on AIM’s ongoing clinical and regulatory strategies, particularly for its lead drug, Ampligen. A focal point of the chat will be the DURIPANC clinical trial, conducted in collaboration with AstraZeneca. This trial explores the combination of Ampligen and AstraZeneca's Imfinzi (durvalumab) for treating metastatic pancreatic cancer—a critical area in oncology.

Additionally, Equels will address positive outcomes from a completed Phase 2 clinical trial involving Merck Sharp & Dohme LLC (Merck), which tested the combination of Ampligen and Merck’s well-known immunotherapy, Keytruda (pembrolizumab), in patients with advanced recurrent ovarian cancer. The findings, which highlighted good tolerability and clinical benefits, were recently showcased at the 40th Annual SITC Meeting.

Investors and interested parties are encouraged to participate actively by submitting their questions ahead of the event via email to aim@jtcir.com. Equels intends to address as many inquiries as possible during the chat. A live webcast of the event will be accessible on AIM's website, with a replay available shortly after the live session for 90 days.

AIM ImmunoTech is dedicated to developing immune-based therapies to combat various cancers, immune disorders, and viral diseases, including COVID-19. Its flagship product, Ampligen, is recognized as a first-in-class investigational drug, showcasing the company's commitment to innovative treatments. For more information, visit aimimmuno.com and follow AIM on social media platforms.

As AIM ImmunoTech (NYSE American: AIM) prepares for its participation in the Virtual Investor Closing Bell Series on December 4, 2025, there are significant elements to consider for investors watching this firm closely. Led by CEO Thomas K. Equels, AIM's strategy focuses on the clinical and regulatory advancements of its investigational drug, Ampligen. This drug, which is currently in clinical trials, shows promise in treating various cancers.

A key highlight from the event will be the discussion around the DURIPANC clinical trial, where Ampligen is being tested alongside AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer. The complexities of this trial are critical for investors to watch, especially given the high unmet medical need in pancreatic cancer treatment. Positive results could significantly enhance AIM’s valuation, as the company aims to position Ampligen as a viable option within the oncology market.

Additionally, the recently completed Phase 2 clinical trial in collaboration with Merck, which studied Ampligen's combination with Keytruda (pembrolizumab) for advanced ovarian cancer, indicates that the drug is well-tolerated and shows clinical benefits. The positive findings presented at the SITC Annual Meeting could catalyze further investment interest and potential partnerships, aimed at accelerating development timelines.

For investors, attending the fireside chat and participating in the Q&A session could provide insights into the management's vision and the potential trajectory for Ampligen. The live webcast offers an opportunity for deeper engagement with the company’s future prospects.

In summary, AIM ImmunoTech’s developments hinge on the outcomes of its clinical trials, and active investor participation in upcoming discussions could provide an advantageous edge. Investors should monitor these updates closely as they could significantly influence market sentiment and stock performance.